0

531739

GENNEX

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GENNEX LABORATORIES LTD. Share Price Today

Investment Returns

Over 1 Month -15.39% Over 3 Months 25.96% Over 6 Months -15.85% Over 1 Year -13.47%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GENNEX LABORATORIES LTD. fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 260.40
  • P/E Ratio (TTM) 16.24
  • Beta 1.35
  • Book Value / share 8.97
  • Return on equity 7.90%
  • EPS (TTM) 0.69
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 2.99
info icon alternate text

GENNEX LABORATORIES LTD. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 36.71
Operating Expense 34.51
Net Profit 2.99
Net Profit Margin (%) 8.14
Earnings Per Share (EPS) 0.13
EBITDA 4.18
Effective Tax Rate (%) 6.56
Particulars DEC 2025 (Values in Cr)
Revenue 28.18
Operating Expense 25.46
Net Profit 4.45
Net Profit Margin (%) 15.79
Earnings Per Share (EPS) 0.18
EBITDA 6.14
Effective Tax Rate (%) 9.52
Particulars SEP 2025 (Values in Cr)
Revenue 29.33
Operating Expense 26.13
Net Profit 4.53
Net Profit Margin (%) 15.44
Earnings Per Share (EPS) 0.19
EBITDA 5.99
Effective Tax Rate (%) 13.38
Particulars JUN 2025 (Values in Cr)
Revenue 25.64
Operating Expense 23.05
Net Profit 4.15
Net Profit Margin (%) 16.18
Earnings Per Share (EPS) 0.18
EBITDA 5.64
Effective Tax Rate (%) 14.43
Particulars MAR 2025 (Values in Cr)
Revenue 23.28
Operating Expense 23.83
Net Profit 1.50
Net Profit Margin (%) 6.44
Earnings Per Share (EPS) 0.07
EBITDA 2.94
Effective Tax Rate (%) 30.73
Particulars MAR 2026 (Values in Cr)
Revenue 119.86
Operating Expense 109.16
Net Profit 16.13
Net Profit Margin (%) 13.45
Earnings Per Share (EPS) 0.67
EBITDA 21.67
Effective Tax Rate (%) 11.56
Particulars MAR 2025 (Values in Cr)
Revenue 94.58
Operating Expense 86.58
Net Profit 14.04
Net Profit Margin (%) 14.84
Earnings Per Share (EPS) 0.62
EBITDA 19.41
Effective Tax Rate (%) 17.70
Particulars MAR 2024 (Values in Cr)
Revenue 86.71
Operating Expense 75.13
Net Profit 13.18
Net Profit Margin (%) 15.20
Earnings Per Share (EPS) 0.70
EBITDA 21.94
Effective Tax Rate (%) 20.13
Particulars MAR 2023 (Values in Cr)
Revenue 65.10
Operating Expense 62.48
Net Profit 4.56
Net Profit Margin (%) 7.00
Earnings Per Share (EPS) 0.26
EBITDA 7.98
Effective Tax Rate (%) 24.12
Particulars MAR 2022 (Values in Cr)
Revenue 61.21
Operating Expense 57.50
Net Profit 3.92
Net Profit Margin (%) 6.40
Earnings Per Share (EPS) 0.33
EBITDA 6.76
Effective Tax Rate (%) 22.98
Particulars MAR 2025 (Values in Cr)
Book Value / Share 7.96
ROE % 10.15
ROCE % 12.40
Total Debt to Total Equity 0.04
EBITDA Margin 17.28
Particulars MAR 2024 (Values in Cr)
Book Value / Share 7.24
ROE % 10.51
ROCE % 13.64
Total Debt to Total Equity 0.03
EBITDA Margin 22.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.46
ROE % 7.91
ROCE % 10.17
Total Debt to Total Equity 0.09
EBITDA Margin 12.02
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3.46
ROE % 9.35
ROCE % 11.78
Total Debt to Total Equity 0.21
EBITDA Margin 10.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.14
ROE % 10.67
ROCE % 13.16
Total Debt to Total Equity 0.16
EBITDA Margin 10.49
Particulars MAR 2025 (Values in Cr)
Book Value / Share 7.87
ROE % 7.90
ROCE % 10.25
Total Debt to Total Equity 0.01
EBITDA Margin 18.47
Particulars MAR 2024 (Values in Cr)
Book Value / Share 7.26
ROE % 9.45
ROCE % 12.50
Total Debt to Total Equity 0.01
EBITDA Margin 22.59
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.39
ROE % 7.41
ROCE % 10.69
Total Debt to Total Equity 0.09
EBITDA Margin 11.20
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3.48
ROE % 9.35
ROCE % 11.78
Total Debt to Total Equity 0.21
EBITDA Margin 10.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.15
ROE % 10.67
ROCE % 13.17
Total Debt to Total Equity 0.16
EBITDA Margin 10.49
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 55.56
Total Assets 256.03
Total Liabilities 256.03
Total Equity 194.58
Share Outstanding 22
Price to Book Ratio 1.53
Return on Assets (%) 7.07
Return on Capital (%) 8.85
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.97
Total Assets 229.98
Total Liabilities 229.98
Total Equity 176.46
Share Outstanding 22
Price to Book Ratio 2.18
Return on Assets (%) 5.72
Return on Capital (%) 7.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 15.06
Total Assets 132.31
Total Liabilities 132.31
Total Equity 86.51
Share Outstanding 18
Price to Book Ratio 1.28
Return on Assets (%) 3.71
Return on Capital (%) 5.62
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 68.02
Total Liabilities 68.02
Total Equity 43.81
Share Outstanding 12
Price to Book Ratio 2.16
Return on Assets (%) 5.76
Return on Capital (%) 7.27
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 58.90
Total Liabilities 58.90
Total Equity 39.70
Share Outstanding 12
Price to Book Ratio 1.24
Return on Assets (%) 6.85
Return on Capital (%) 8.58
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 55.56
Total Assets 218.38
Total Liabilities 218.38
Total Equity 184.79
Share Outstanding 22
Price to Book Ratio 1.53
Return on Assets (%) 6.42
Return on Capital (%) 7.55
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.96
Total Assets 205.33
Total Liabilities 205.33
Total Equity 170.75
Share Outstanding 22
Price to Book Ratio 2.18
Return on Assets (%) 5.74
Return on Capital (%) 6.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 14.45
Total Assets 96.22
Total Liabilities 96.22
Total Equity 79.01
Share Outstanding 18
Price to Book Ratio 1.28
Return on Assets (%) 4.73
Return on Capital (%) 5.7
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 68.20
Total Liabilities 68.20
Total Equity 43.99
Share Outstanding 12
Price to Book Ratio 2.16
Return on Assets (%) 5.75
Return on Capital (%) 7.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 59.08
Total Liabilities 59.08
Total Equity 39.89
Share Outstanding 12
Price to Book Ratio 1.24
Return on Assets (%) 6.83
Return on Capital (%) 8.55
Particulars MAR 2025 (Values in Cr)
Net Income 21.39
Cash from Operations -7.57
Cash from Investing 0.82
Cash from Financing 4.56
Net change in Cash -5.40
Free Cash Flow 1.36
Particulars MAR 2024 (Values in Cr)
Net Income 16.49
Cash from Operations -46.68
Cash from Investing 18.91
Cash from Financing 73.68
Net change in Cash 45.91
Free Cash Flow -46.68
Particulars MAR 2023 (Values in Cr)
Net Income 6.37
Cash from Operations 23.67
Cash from Investing -38.32
Cash from Financing 21.03
Net change in Cash 6.38
Free Cash Flow 63.46
Particulars MAR 2022 (Values in Cr)
Net Income 5.27
Cash from Operations 13.01
Cash from Investing -2.46
Cash from Financing -1.83
Net change in Cash 7.61
Free Cash Flow 14.61
Particulars MAR 2021 (Values in Cr)
Net Income 5.06
Cash from Operations 0.09
Cash from Investing -0.02
Cash from Financing 1.61
Net change in Cash 0.15
Free Cash Flow 0.17
Particulars MAR 2025 (Values in Cr)
Net Income 17.06
Cash from Operations -9.51
Cash from Investing 2.63
Cash from Financing 1.52
Net change in Cash -5.35
Free Cash Flow -3.56
Particulars MAR 2024 (Values in Cr)
Net Income 14.86
Cash from Operations -32.33
Cash from Investing 0.92
Cash from Financing 79.01
Net change in Cash 46.51
Free Cash Flow -29.49
Particulars MAR 2023 (Values in Cr)
Net Income 6.01
Cash from Operations -14.45
Cash from Investing -0.76
Cash from Financing 21.35
Net change in Cash 6.13
Free Cash Flow -12.22
Particulars MAR 2022 (Values in Cr)
Net Income 5.27
Cash from Operations 7.74
Cash from Investing -1.26
Cash from Financing 1.86
Net change in Cash 7.24
Free Cash Flow 8.13
Particulars MAR 2021 (Values in Cr)
Net Income 5.06
Cash from Operations 0.09
Cash from Investing -0.02
Cash from Financing 1.61
Net change in Cash 0.15
Free Cash Flow 0.17
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 31.51 13.02 1.52 241.47 23.12 38.85
BLISS GVS PHARMA LTD. 492.50 39.98 4.37 5223.27 118.35 495.00
CIPLA LTD. 1440.30 30.57 3.37 116353.96 1165.55 1672.20
FERMENTA BIOTECH LTD. 365.50 16.12 2.64 1075.70 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 31.51 22.03 4.05 241.47 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 538.05 24.12 4.20 1555.54 490.00 789.95
ASTRAZENECA PHARMA IND LT 8382.65 109.48 24.01 20956.63 7630.00 9850.00
BLISS GVS PHARMA LTD. 492.50 53.13 4.52 5223.27 118.35 495.00

GENNEX LABORATORIES LTD. shareholding pattern

Holding
76.36%
23.62%
17.42%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

GENNEX LABORATORIES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
10.72 -0.09 redarrow
red-green-graph indicator
5 Bearish
11 Bullish
  • 5 Days 10.70
  • 26 Days 10.70
  • 10 Days 10.70
  • 50 Days 10.60
  • 12 Days 10.70
  • 100 Days 10.90
  • 20 Days 10.70
  • 200 Days 11.80
10.74 PIVOT
First Support 10.51 First Resistance 10.97 Second Support 10.28 Second Resistance 11.20 Third Support 10.05 Third Resistance 11.43
RSI 50.60 ADX 34.39 MACD 0.01 Williams % R -71.20 Commodity Channel Index (CCI) -12.73
Date 2026-06-25 Week 339195.00 Same Day 96302.00 Month 456537.00
1 Year 1.36 3 Year 0.95
Over 1 Month
-15.39% down
Over 1 Year
-13.47% down
Over 3 Months
25.96% down
Over 3 Years
16.10% down
Over 6 Months
-15.85% down
Over 5 Years
4.57% down

GENNEX LABORATORIES LTD. Corporate Actions

Ex-Date Old FV NEW FV Record Date
14 Dec 2009 10.0 1.0 15 Dec 2009

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Gennex Laboratories Ltd?

Answer Field

Gennex Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 10.72 as on Jun 25 2026 03:30 PM.

What is the Market Cap of Gennex Laboratories Ltd Share?

Answer Field

The market cap of Gennex Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 260.40 as on Jun 25 2026 03:30 PM.

What is the 52 Week High and Low of Gennex Laboratories Ltd?

Answer Field

The 52 Week High and Low of Gennex Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 17.25 and ₹ 7.05.

What is 1 year return for Gennex Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -13.47%.

What is the P/E Ratio of Gennex Laboratories Ltd Share?

Answer Field

As on Jun 25 2026 03:30 PM the price-to-earnings (PE) ratio for Gennex Laboratories Ltd share is 16.24.

What is the PB ratio of Gennex Laboratories Ltd Share?

Answer Field

As on Jun 25 2026 03:30 PM, the price-to-book (PB) ratio for Gennex Laboratories Ltd share is 8.97.

How to Buy Gennex Laboratories Ltd Share?

Answer Field

You can trade in Gennex Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gennex Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Gennex Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gennex Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image
Get Free Demat Account*
+91
close-img
Authorise with OTP
Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|